Overflow by Gliflozins: Mechanisms and Consequences of the Off-Target Effects of SGLT2 Inhibitors
October 23, 2020 | 10:30 AM - 12:30 PM
Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.
Basic/Clinical Science Session
Overflow by Gliflozins: Mechanisms and Consequences of the Off-Target Effects of SGLT2 Inhibitors
October 23, 2020 | 10:30 AM - 12:30 PM
Location: Simulive
Session Description
Sodium-glucose cotransporter 2 (SGLT2) inhibitors are new treatments approved by the US Food and Drug Administration for individuals with diabetic kidney disease. Although a primary mechanism of action is known, several additional renal and extrarenal perturbations have been discovered. The nature and contribution of these "off-target" effects are being elucidated. This session explores these effects and whether they play an instrumental or confounding role in the positive effects of SGLT2 inhibitors on renal and cardiovascular disease.
Learning Objective(s)
- Identify the mechanisms and consequences of sodium-hydrogen exchanger 3 (NHE3) inhibition by SGLT2 inhibitors
- Discuss the effects of SGLT2 inhibitors on divalent cation homeostasis, including calcium and magnesium
- Elucidate the potential role of uric acid excretion for observed benefits of SGLT2 inhibitors on kidney and cardiovascular disease
- Describe the direct effects of SGLT2 inhibitors on mitochondria and their downstream consequences
Learning Pathway(s)
- Cell and Transport Physiology
- Diabetes and Metabolism
Moderators
- Carolyn M. Ecelbarger, PhD
- Carol A. Pollock, MD, PhD
Presentations
- Role of Sodium-Hydrogen Exchanger 3 (NHE3) Inhibition and Sodium-Glucose Cotransporter 2 (SGLT2)-Mediated NHE3 Inhibition in the Diabetic Kidney
10:30 AM - 11:00 AM
Alicia A. McDonough, PhD
Role of Sodium-Hydrogen Exchanger 3 (NHE3) Inhibition and Sodium-Glucose Cotransporter 2 (SGLT2)-Mediated NHE3 Inhibition in the Diabetic Kidney
October 23, 2020 | 10:30 AM - 11:00 AM
Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.
- Mechanisms of SGLT2 Inhibitor Nephroprotection Beyond Glomerular Hemodynamics
11:00 AM - 11:30 AM
Richard E. Gilbert, MD, PhD, FASN
Richard E. Gilbert, MD, PhD, FASN
Mechanisms of SGLT2 Inhibitor Nephroprotection Beyond Glomerular Hemodynamics
October 23, 2020 | 11:00 AM - 11:30 AM
Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.
- The Role of Uric Acid in Cardiorenal Benefits of SGLT2 Inhibition
11:30 AM - 12:00 PM
Clifford J. Bailey, PhD
Clifford J. Bailey, PhD
Cliff Bailey is Emeritus Professor of Clinical Science at Aston University in Birmingham, England. He is a Fellow of the Royal College of Physicians of Edinburgh and a Fellow of the Royal College of Pathologists. He has been a Royal Society visiting scientist at the University of Southern California, Los Angeles, and a visiting scientist at Hanover Medical School in Germany. He has served on medical and scientific committees of Diabetes UK (formerly the British Diabetic Association), Society for Endocrinology, and European Association for the Study of Diabetes. Professor Bailey has held various editorial positions, including endocrine section editor of British Journal of Pharmacology and editorial board member of Diabetes, Obesity and Metabolism, LancetDE and Primary Care Diabetes. He is presently senior editor of Diabetes and Vascular Disease Research. He has been an expert witness for drug licensing authorities, regulatory agencies and other national and international review bodies. He received the 2013 Lunar Society medal and the 2015 Banting Lecture award. His research is mainly directed towards the pathogenesis and treatment of diabetes, especially the development of new agents to improve insulin action and reduce obesity, and the therapeutic application of surrogate beta-cells. He has published over 400 research papers and reviews, and five books.
The Role of Uric Acid in Cardiorenal Benefits of SGLT2 Inhibition
October 23, 2020 | 11:30 AM - 12:00 PM
Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.
- Alterations in Mitochondrial Function by SGLT2 Inhibitors
12:00 PM - 12:30 PM
Tetsuji Miura, MD, PhD
Alterations in Mitochondrial Function by SGLT2 Inhibitors
October 23, 2020 | 12:00 PM - 12:30 PM
Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.
